R Squared’s PTC Therapeutics PTCT Stock Holding History

R Squared’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,750	Closed	-$79K	–	1197
2024 Q4	$79K	Buy	+1,750	New	+$74.9K	0.08%	331

Other funds holding PTCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

R Squared's PTCT Position: Q1 2025 in Review

R Squared sold out of PTC Therapeutics (PTCT) in Q1 2025, closing a stake of 1,750 shares — an estimated $79K sold.

R Squared first reported a position in PTCT in Q4 2024 and held it in 1 quarter. The position peaked at $79K in Q4 2024. 260 funds tracked by Wall St. Rank hold PTCT as of Q1 2025.

R Squared reported no remaining PTC Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 1,750 PTC Therapeutics shares in Q1 2025, an estimated $79K.
R Squared first reported a position in PTC Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's PTC Therapeutics position peaked at $79K in Q4 2024.
260 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.